Hairy cell leukemia

What is Hairy cell leukemia?

Hairy cell leukemia (HCL) is a rare type of blood cancer that affects B lymphocytes, a type of white blood cell that normally helps fight infections. The disease gets its name from the distinctive “hairy” projections that extend from the abnormal cells when viewed under a microscope. HCL primarily affects middle-aged adults, with men being four times more likely to develop the condition than women. With approximately 1,000 new cases diagnosed annually in the United States, this represents one of the rarest forms of leukemia, accounting for only 2% of all leukemia cases.

Key statistics

Symptoms

Common symptoms: Fatigue, weakness, frequent infections, easy bruising, enlarged spleen, abdominal fullness, unexplained weight loss, pale skin.

The symptoms of hairy cell leukemia typically develop gradually and are often subtle in the early stages. Fatigue and weakness are among the most common initial complaints, occurring as abnormal cells crowd out healthy blood cells. Patients frequently experience recurrent or persistent infections due to low white blood cell counts, including respiratory tract infections, skin infections, or unusual opportunistic infections. Easy bruising and bleeding occur when platelet counts drop, manifesting as small red spots under the skin (petechiae), nosebleeds, or prolonged bleeding from minor cuts. Splenomegaly, or enlargement of the spleen, affects nearly all patients and can cause a feeling of fullness in the left upper abdomen, early satiety, and abdominal discomfort. Some patients notice unexplained weight loss, night sweats, or a general sense of feeling unwell that persists despite rest.

Causes and risk factors

Hairy cell leukemia is an acquired cancer, meaning it develops during a person’s lifetime rather than being inherited. The primary genetic driver is the BRAF V600E mutation, found in over 95% of cases. This mutation affects the BRAF protein, which normally helps regulate cell growth and division. When mutated, it leads to uncontrolled proliferation of abnormal B lymphocytes.

Submit Your Paper

The exact trigger for this mutation remains unknown, and unlike many other cancers, HCL has few identified risk factors. Age is the primary risk factor, with most cases occurring in middle-aged adults. Male sex significantly increases risk, though the reason for this gender disparity is unclear. Unlike some leukemias, there is no strong evidence linking HCL to radiation exposure, chemotherapy, smoking, or occupational hazards. The disease appears to occur sporadically without clear environmental triggers or familial clustering.

Prevention

Currently, there are no proven methods to prevent hairy cell leukemia. Since the disease is acquired rather than inherited and lacks identified environmental risk factors, standard cancer prevention strategies do not apply. There is no routine screening program for HCL due to its rarity and the lack of early detection markers. Genetic testing for BRAF mutations is not recommended for asymptomatic individuals, as this mutation develops somatically in cancer cells rather than being inherited. Family members of HCL patients do not have an increased risk of developing the disease. The best approach is maintaining general health through regular medical check-ups, which may help identify symptoms early if they develop.

Complications

Without treatment, hairy cell leukemia can lead to life-threatening complications. Severe pancytopenia (low counts of all blood cell types) increases the risk of overwhelming infections, uncontrolled bleeding, and severe anemia requiring transfusions. The enlarged spleen may rupture, causing internal bleeding that requires emergency surgery. Neutropenia makes patients vulnerable to serious bacterial, viral, and fungal infections that can become systemic and fatal.

Long-term complications may include secondary cancers, though this risk appears lower than with some other hematologic malignancies. Some patients develop autoimmune complications affecting joints, skin, or blood vessels. Bone marrow fibrosis can occur, making future treatments more challenging. Even with successful treatment, some patients experience chronic fatigue or increased susceptibility to infections that can persist for years.

Diagnosis

Diagnosing hairy cell leukemia requires a combination of clinical presentation, laboratory findings, and specialized testing. Initial blood work typically reveals pancytopenia with characteristic “hairy cells” visible on peripheral blood smear examination. However, these abnormal cells may be sparse, requiring careful review by experienced hematopathologists.

Bone marrow biopsy is essential for diagnosis but often results in a “dry tap” because the abnormal cells create fibrosis that prevents aspiration of liquid marrow. Core bone marrow biopsy shows the characteristic infiltration pattern of hairy cells. Flow cytometry identifies specific markers including CD11c, CD25, CD103, and annexin A1 that are highly characteristic of HCL. Immunohistochemistry staining for tartrate-resistant acid phosphatase (TRAP) is classically positive. Genetic testing for the BRAF V600E mutation confirms the diagnosis in most cases and can be performed on blood or bone marrow samples. CT or MRI imaging reveals splenomegaly and may identify enlarged lymph nodes, though significant lymphadenopathy is uncommon in HCL.

Treatment

Treatment for hairy cell leukemia has evolved significantly, offering excellent outcomes for most patients. Not all patients require immediate treatment; those with mild symptoms and adequate blood counts may be monitored with active surveillance.

First-line treatments include purine analogs such as cladribine and pentostatin. Cladribine, administered as a single seven-day course, achieves complete remission in 80-95% of patients. Pentostatin requires multiple treatments over several months but offers similar efficacy. Both drugs work by interfering with DNA synthesis in the abnormal cells.

For patients with relapsed or refractory disease, targeted therapy with vemurafenib, a BRAF inhibitor, specifically targets the mutated protein driving the cancer. Moxetumomab pasudotox, an immunotoxin that targets CD22 on hairy cells, is approved for relapsed disease after at least two prior treatments.

Supportive care includes antibiotics for infections, blood transfusions for severe anemia or thrombocytopenia, and splenectomy in rare cases where the enlarged spleen causes severe symptoms or doesn’t respond to systemic therapy.

Prognosis

The prognosis for hairy cell leukemia is excellent with appropriate treatment. Five-year survival rates approach 96-100%, making it one of the most treatable forms of leukemia. Most patients achieve complete remission with first-line therapy and can expect near-normal life expectancy. The disease follows an indolent course, meaning it typically progresses slowly.

However, HCL is generally considered incurable, and most patients will eventually experience relapse, often years or decades after initial treatment. Fortunately, the disease usually remains responsive to retreatment, and many patients live with their condition as a manageable chronic illness. Quality of life during remission is typically excellent, with most patients returning to normal activities and work. The development of targeted therapies has further improved outcomes for patients with relapsed disease.

Quality of life

Most patients with hairy cell leukemia can maintain excellent quality of life, especially during remission periods. Regular exercise is encouraged as tolerated, helping combat fatigue and maintain overall health. However, contact sports should be avoided if platelet counts are low due to bleeding risk.

Diet should focus on food safety, particularly avoiding unpasteurized dairy products, undercooked meats, and unwashed fruits and vegetables when white blood cell counts are low. A balanced, nutritious diet supports overall health and recovery. Adequate sleep is crucial, as fatigue is common both from the disease and treatments.

Mental health support is important, as the diagnosis of any cancer can cause anxiety and depression. Many patients benefit from counseling or support groups. Workplace accommodations may be necessary during treatment periods, but most patients can return to full work capacity during remission. Travel is generally safe during remission, though patients should consult their healthcare team about vaccination requirements and infection precautions.

Pregnancy and fertility

Pregnancy considerations in hairy cell leukemia are complex due to the disease’s rarity and typical occurrence in middle-aged individuals. The disease itself may affect fertility indirectly through fatigue and overall health impacts. Treatment with purine analogs like cladribine and pentostatin can affect fertility and are contraindicated during pregnancy due to potential teratogenic effects.

Women of childbearing age should use effective contraception during treatment and for several months afterward. For pregnant women diagnosed with HCL, treatment decisions require careful multidisciplinary planning involving hematology, obstetrics, and neonatology specialists. In some cases, treatment may be delayed until after delivery if the disease is stable. Genetic counseling is generally not necessary since HCL is acquired rather than inherited.

Children

Hairy cell leukemia is extraordinarily rare in children, with fewer than 50 pediatric cases reported in medical literature. When it does occur in children, the presentation and treatment approach are similar to adults, though dosing must be adjusted for body size and developmental considerations. The prognosis appears equally favorable in the rare pediatric cases. Long-term follow-up is particularly important in children to monitor for late effects of treatment and ensure normal growth and development.

When to see a doctor

Seek immediate medical attention for signs of serious infection including fever, chills, persistent cough, or unusual infections that don’t respond to standard treatment. Emergency care is needed for severe bleeding that doesn’t stop, severe abdominal pain (which could indicate splenic rupture), or signs of severe anemia such as chest pain or severe shortness of breath.

Schedule routine medical care for persistent fatigue lasting more than two weeks, easy bruising or bleeding, recurrent infections, unexplained weight loss, or a feeling of fullness in the upper left abdomen. While these symptoms are common and usually have benign causes, they warrant medical evaluation, especially when multiple symptoms occur together or persist despite conservative management.

Regional context

Limited data exists on hairy cell leukemia prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) or broader Eastern Mediterranean areas. The disease’s rarity makes regional epidemiological studies challenging, and most published data comes from North American and Western European populations. Genetic factors influencing HCL susceptibility in different ethnic populations remain understudied. Healthcare professionals and researchers in these regions are encouraged to contribute case reports and epidemiological data to the Global Medical Journal to improve understanding of HCL’s global distribution and any regional variations in presentation or outcomes.

Research and clinical trials

Current research in hairy cell leukemia focuses on improving treatment for relapsed disease and understanding resistance mechanisms. Studies are investigating combination therapies pairing BRAF inhibitors with other targeted agents. Research into minimal residual disease monitoring aims to predict which patients are more likely to relapse.

Novel immunotherapies, including checkpoint inhibitors and CAR-T cell therapy, are being explored. Scientists are also studying the role of additional mutations beyond BRAF V600E that may influence disease behavior and treatment response. Patients interested in clinical trials should consult ClinicalTrials.gov and discuss options with their healthcare team, particularly if they have relapsed or refractory disease.

Frequently asked questions

Is hairy cell leukemia hereditary?

No, hairy cell leukemia is an acquired cancer that develops during a person’s lifetime. Family members do not have an increased risk of developing the disease.

How long can someone live with hairy cell leukemia?

With modern treatment, most patients have near-normal life expectancy. Five-year survival rates are 96-100%, and many patients live decades with well-controlled disease.

Will I need chemotherapy for the rest of my life?

No, treatment for HCL is typically given in courses rather than continuously. Many patients remain in remission for years or decades between treatments.

Can hairy cell leukemia be cured?

While HCL is highly treatable and most patients achieve complete remission, it is generally considered incurable as most patients will eventually relapse. However, it remains responsive to retreatment.

Are there dietary restrictions with hairy cell leukemia?

During treatment or when blood counts are low, patients should avoid foods that carry infection risk, such as unpasteurized products and undercooked meats. Otherwise, a normal, balanced diet is recommended.

Support and resources

• Leukemia & Lymphoma Society – Comprehensive patient support and information
• Hairy Cell Leukemia Foundation – Disease-specific patient advocacy organization
• National Organization for Rare Disorders (NORD) – Rare disease patient support
• Orphanet – European database of rare diseases
• EURORDIS – European Organisation for Rare Diseases
• American Cancer Society – General cancer support and information

Related conditions

• Chronic lymphocytic leukemia
• Marginal zone lymphoma
• Waldenström macroglobulinemia
• Prolymphocytic leukemia
• Splenic lymphoma

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.